Sarepta Downplays Negative Results to Pursue Expanded Indication for Duchenne Therapy

Despite missing its pivotal phase 3 primary efficacy endpoint, Sarepta is sailing confidently into a supplemental application to remove the age limitation on Elevidys (delandistrogene moxeparvovec-rokl), its gene therapy for children with Duchenne muscular dystrophy (DMD).
Source: Drug Industry Daily